Analysis

Obama's FDA Leaves Mark With Last-Minute Policy Blitz

Law360, New York (January 20, 2017, 8:39 PM EST) -- The U.S. Food and Drug Administration capped off the Obama administration with a flurry of bold policy statements on drug and device regulation, potentially influencing or hamstringing a Trump administration that has flirted with greatly relaxed oversight, attorneys say.

The last-minute blitz included more than 20 guidances that the FDA published during the final 10 days of Barack Obama's presidency. The guidances explored many important subjects, including biosimilars and promotion of prescription drugs, and in some cases were in danger of getting shelved if not published by Obama's FDA.

"The end of an administration is a good opportunity to push things...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!